Ypsomed's Transformation to Pure-Play Self-Injection Delivers Record Wins and a New Platform Generation
Pure-Play Focus Delivers Record Wins
Ypsomed's long-awaited transformation is complete. After four years of divesting its consumer and diabetes care businesses, the Swiss device maker is now a focused pure-play in self-injection systems. CEO Simon Michel opened the call with a simple verdict:
That record: 44 new project wins in the year, versus a historical average of 40, with roughly half in biosimilars and a third in incretins. The company now serves over 130 clients, and no single customer exceeds 15% of revenue.The transformation is now history.
The shift is visible in the sales mix. Auto injectors remain the growth engine, with the 1 mL and 2.25 mL platforms leading volume gains. CFO Samuel Kunzli noted that incretins contributed roughly one-third of the CHF 100 million organic growth in delivery systems. But management is careful to emphasize that GLP-1 is not the whole story. "We have a very broad spectrum," Michel said, pointing to 15 deals in incretins, 15 in autoimmune diseases, and the rest scattered across oncology, neurology, and hormone therapy.
The Next S-Curve: Recyclable Platforms and Clear-to-Clinic
The more interesting strategic shift is the launch of three next-generation platforms—YpsoLoop, YpsoDot, and YpsoFlow—all designed to be fully recyclable. These are not incremental improvements; they extend Ypsomed's IP protection into the 2040s. "We have taught our organization 6 years ago with the Ecodesign guidelines how to do that," Michel explained, adding that every new innovation must now be based on the recycling principle. New platforms are not yet revenue-generating, but management expects the first deals to be signed in fiscal 2027–28.
Equally important is the YpsoFit program, which has cut the time to clinical trial supply from 18 months to 6 months by pre-documenting and pre-validating the device. This is a differentiator for small biotechs, who often lack the resources for lengthy regulatory work. "We want to be in the pipeline of the small biotech to then end up in the hands of pharma," Michel said.
On the competitive front, the company's dual-platform strategy—offering both auto-injectors and pens—is becoming a key advantage. Analysts pressed on whether a shift towards pens (which can replace multiple auto-injectors per dose) could hurt margins. Michel's response was reassuring: “For us, the good message is that we have both product platforms in our portfolio. This makes us hugely unique.” — Simon Michel, CEO · 2026-05-20 He acknowledged that pens are less lucrative per volume but argued they provide flexibility and customer retention.
Financial Discipline and Mid-Term Outlook
The financial results underscore the operational leverage now available. Sales reached CHF 731 million, with delivery systems up 20% to CHF 601 million. EBIT came in at CHF 196 million, a 33% margin, and operating cash flow exceeded CHF 300 million. The company used the cash to reduce debt and double the dividend, maintaining a 35% payout policy. Net debt to EBITDA stands at a conservative 0.8x.
Guidance for fiscal 2026-27 is for 12–15% growth in delivery systems (own devices) and EBIT of CHF 210–230 million, keeping the margin above 33%. Midterm, the company targets sales of CHF 0.9–1.1 billion and EBIT of CHF 280–340 million by the end of the decade. The China for China strategy is already yielding cost advantages, and the Schwerin II expansion is on track.
Analysts questioned the slower second-half growth, but management pointed to the phasing of new capacity and the ramp-up of the Schwerin II plant. “We expect to be in '27, '28 free cash flow positive,” — Samuel Kunzli, CFO · 2026-05-20 said Kunzli, as CapEx peaks this year and then declines.
The call also addressed geopolitical risks. On tariffs, the company is mostly insulated because customers ship ex-works from Switzerland or Germany. The only tangible impact is a 15% tariff on plastic molding tools, which is minor. On oral GLP-1s, Michel argued they will expand the market rather than cannibalize injectables, as they target a lighter-weight lifestyle segment. “GLP-1, again, it is just about to start,” — Simon Michel, Chief Executive Officer · 2025-11-12 he said on the prior call, and now we see traction. “We have not contracted yet the full 5 days of the capacity we are going to have by 2030, '31,” — Simon Michel, Chief Executive Officer · 2025-11-12 he added, implying upside if demand accelerates.
Prior calls had already flagged the transformation and midterm ambition, but this report delivers the first full-year evidence that the model works. The record deal wins, the new platform launches, and the cash generation all point to a company at an inflection point.